Financial Data and Key Metrics Changes - Consolidated revenue for 2022 increased by 16% to $11.4 million compared to $9.9 million in 2021, driven by improved revenue on the TRxADE platform and TRxADE Prime [39] - TRxADE platform revenue increased by 10%, while TRxADE Prime revenue grew by 46% in 2022 compared to 2021 [39] - Net loss for 2022 was $3.9 million or $0.41 loss per share, an improvement from a net loss of $5.3 million or $0.65 loss per share in 2021 [41] - Gross profit improved by $700,000 but remained consistent at 48% as a percentage of revenue year-over-year [40] Business Line Data and Key Metrics Changes - TRxADE Prime saw a gross margin improvement from a negative 12% in 2021 to a positive 1% in 2022, reflecting a 13% improvement [15] - Community specialty pharmacy revenue decreased by 29% in 2022 compared to 2021 [39] Market Data and Key Metrics Changes - The company has over 14,400 registered members on its platform, with approximately 1,212 new members added in fiscal 2022 compared to 790 in fiscal 2021 [12] - The independent pharmacy market maintains an estimated annual purchasing power of approximately $67 billion [10] Company Strategy and Development Direction - The company is focusing on innovation and partnerships to drive its core business-to-business strategy while diversifying its revenue base [18] - Plans to sell subsidiary companies are part of the strategy to concentrate on the core business model [13] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of technology and product development to support local pharmacies and enhance customer service [9] - The company aims to improve gross margins and reduce overhead costs moving forward [39] Other Important Information - Cash and cash equivalents decreased to $1.1 million as of December 31, 2022, from $3.1 million in 2021, primarily due to inventory purchases and legal settlements [17] Q&A Session Summary Question: Status of speaking with group purchasing organizations related to TRxADE Prime - Management indicated that they are working with approximately 1,300 new pharmacies and aim to increase this to 1,500 [21][23] Question: Future liability for the SOSRx partnership - Management confirmed there are no future liabilities related to the SOSRx partnership [25][45] Question: Mix between branded and generics on the TRxADE platform - The current mix is approximately 60% generics and 40% brand, with a goal to shift towards 70%-75% generics [54] Question: Constraints with overseas manufacturing - Management stated that supply chain issues have returned to normal post-COVID [55] Question: Streamlining of operating expenses - Management indicated that streamlining will focus on technology and professional fees [56]

Financial Performance - Revenues for the year ended December 31, 2022, increased by $1,558,832 or 15.8% to $11,448,265, compared to $9,889,433 for 2021[355] - Gross profit for the year ended December 31, 2022, was $5,451,216, representing a 14.9% increase from $4,745,965 in 2021[355] - Integra Pharma Solutions' revenue increased by $1,503,506 or 46% due to increased sales volume and pricing changes[356] - Net loss decreased by $1,406,015 to $3,909,868 for the year ended December 31, 2022, compared to a net loss of $5,315,883 for the year ended December 31, 2021, representing a 26% improvement[366][378] Operating Expenses - Total operating expenses decreased by 1.6% to $9,875,511 for the year ended December 31, 2022, compared to $10,038,258 in 2021[355] - Loss on inventory investment was $875,520 for the year ended December 31, 2022, compared to $1,225,141 in 2021[362] - Interest expense increased significantly to $315,217 for the year ended December 31, 2022, from $23,590 in 2021, due to funding agreements[365] Cash Flow and Capital - Cash and cash equivalents were $1,133,633 at December 31, 2022, down from $3,122,578 at the end of 2021[368] - Cash used by operations decreased to $1,525,929 in 2022 from $2,566,226 in 2021, a reduction of 41%[379] - Cash flows from operating activities improved by $1,040,297, reflecting a 41% decrease in cash used compared to the previous year[378] - Cash used in investing activities increased significantly to $427,845 in 2022 from $22,596 in 2021, primarily for capitalized software investments[380] - The company raised approximately $1.3 million in 2022 through the exercise of warrants and a stock placement of 920,000 shares at $1.15 per share[375] - The company anticipates the need for additional funding in the next 12 months to maintain operations and support potential acquisitions[346] - The company anticipates needing additional capital or debt funding to support ongoing operations and expansion efforts[373][376] Liabilities and Current Position - Working capital decreased by $3,501,886 to negative $53,668 as of December 31, 2022, compared to $3,448,218 as of December 31, 2021[344] - Current liabilities increased by $1,220,765 to $2,146,791 for the year ended December 31, 2022, primarily due to increased notes payable related to a joint venture[372] Taxation and Legal Matters - The company is subject to income taxes in the U.S., requiring significant judgments and estimates for the consolidated income tax provision[397] - Deferred income taxes arise from temporary differences between tax and financial statement recognition of revenue and expense, with considerations of past operating results and future taxable income forecasts[398] - Changes in tax laws and rates could materially impact the company's tax expense and cash flows in the future[399] - The company may face various claims and legal actions, with liabilities recorded when a loss is probable and reasonably estimable[400] - The likelihood of loss from contingencies is reviewed quarterly, and meaningful estimates can be complex due to dependence on future negotiations[401] Research and Development - Technology, research, and development expenditures were $1,160,856 for 2022, a decrease from $1,367,895 in 2021[359] - The company plans to continue developing information technology used in its subsidiaries and will rely on customer feedback for product improvements[346] Stock-Based Compensation - Stock-based compensation is accounted for based on the grant date fair value, recognized as compensation expense over the vesting period[402] - The company adopted ASU 2018-07 for accounting of share-based payments granted to non-employees effective January 1, 2019[402] Reporting and Compliance - The company is classified as a "smaller reporting company" and is not required to provide certain market risk disclosures[405] - The company has no outstanding off-balance sheet arrangements as of December 31, 2022[384]

Financial Data and Key Metrics Changes - Consolidated revenues for Q3 2022 decreased by 6% to $2.4 million compared to $2.6 million in Q3 2021, primarily driven by declines in TRxADE Prime and Community Specialty Pharmacy [19] - Gross profit increased to $1.4 million or 58% of revenue, up from $1.3 million and 50% of revenue in Q3 2021, attributed to increased revenues from the TRxADE platform and improved gross margins of TRxADE Prime [23] - Net loss for Q3 2022 was negative $0.5 million or negative $0.06 per share, compared to a net loss of negative $1.3 million or negative $0.16 per share in Q3 2021 [25] Business Line Data and Key Metrics Changes - Revenues generated by the TRxADE platform increased by 6% in Q3 2022 compared to the same quarter in 2021 [19] - TRxADE Prime experienced an 11% decline in revenue for Q3 2022 compared to Q3 2021, but gross margin improved to a positive 3% from a negative 6% [20][21] - The volume of sales processed across the TRxADE platform increased by 18% in Q3 2022 compared to the same quarter in 2021 [16] Market Data and Key Metrics Changes - The company reported over 14,100 registered members on its platform, with approximately 291 new members added in Q3 2022, compared to 195 in Q3 2021 [15] - The Community Specialty Pharmacy's revenue decline was partially attributed to decreased sales in the last week of September due to Hurricane Ian [22] Company Strategy and Development Direction - The company is focusing on strategic partnerships to enhance its core business and diversify revenue streams, including partnerships with insurance brokerage firms and telemedicine services [8][28] - The company aims to digitalize the retail pharmacy experience through optimization of drug procurement and patient engagement [9] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the ongoing challenges posed by COVID-19, increased interest rates, and inflation, but remains optimistic about the company's growth trajectory [4] - The company is working towards operational breakeven and is focused on improving both top-line and bottom-line performance [36] Other Important Information - Cash and cash equivalents were $0.3 million as of September 30, 2022, down from $3.1 million as of December 31, 2021, primarily due to expenditures on salaries, inventory, and legal settlements [26] - The company closed the sale of approximately $1.75 million of common stock, with net cash proceeds of approximately $1.5 million intended for working capital and strategic growth [17] Q&A Session Summary Question: Can you talk about the strategic direction for TRxADE Prime? - Management emphasized a focus on both top-line growth and gross margin improvement, implementing AI to enhance pricing and customer service [31] Question: Any updates on Bonum Health and its rollout? - Management indicated that Bonum Health is still in a nascent phase, seeking strategic buyers or joint ventures to enhance its offering [32] Question: Will the engagement of insurance brokerage firms lead to faster uptake than pharmacy partners? - Management confirmed that the intention is to target uninsured small businesses through these brokerage firms [34] Question: What is the status of the SOSRx joint venture? - Management noted that adoption is slow as manufacturers are accustomed to traditional business methods, similar to the early days of TRxADE [35] Question: Can we expect operational breakeven in the first half of next year? - Management stated that while they cannot predict a timeline, they are working towards positive financial results [36] Question: What was the impact of Hurricane Ian on revenue? - Management confirmed that the last week of Q3 was affected, but patients returned in the subsequent quarter [42][43] Question: Were there any significant one-time impacts in the quarter? - Management mentioned a recovery of $164,000 from a previous bad debt write-off, but no other significant one-time impacts were noted [45]

TRxADE HEALTH, Inc. (NASDAQ:MEDS) Q2 2022 Earnings Conference Call July 25, 2022 5:00 PM ET Company Participants Suren Ajjarapu - Founder, Chairman and CEO Janet Huffman - Chief Financial Officer Conference Call Participants Allen Klee - Maxim Group Howard Halpern - Taglich Brothers Operator Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to TRxADE HEALTH Second Quarter 2022 Earnings Conference Call. During today’s presentation, all parties will be in a listen-only mode. Following t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _______ to _______ Commission File Number: 001-39199 TRxADE HEALTH, INC. (Exact name of registrant as specified in its charter) | Delaware | 46-3673928 | | --- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _______ to _______ Commission File Number: 001-39199 TRxADE HEALTH, INC. (Exact name of registrant as specified in its charter) | Delaware | 46-3673928 | | -- ...

OR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 (Exact name of registrant as specified in its charter) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: _____________to______________ Commission File Number: 001-39199 TRxADE HEALTH, INC. | Delaware | 46-3673928 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _______ to _______ Commission File Number: 001-39199 TRxADE HEALTH, INC. (Exact name of registrant as specified in its charter) | Delaware | 46-3673928 | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 OR FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _______ to _______ Commission File Number: 001-39199 TRxADE HEALTH, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _______ to _______ Commission File Number: 001-39199 TRXADE GROUP, INC. (Exact name of registrant as specified in its charter) | Delaware | 46-3673928 | | --- | --- ...